A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy

A Phase II Study of Weekly Docetaxel in Combination with Capecitabine in Advanced Gastric and Gastroesophageal Adenocarcinomas

(2010) Shelly S. Lo et al.   ONCOLOGY

Phase II study of S-1 and irinotecan combination chemotherapy as a first-line therapy for patients with advanced gastric cancer. Korean Cancer Study Group Protocol ST05-02

(2009) Hye J KANG et al.   Asia-Pacific Journal of Clinical Oncology

SPARC Is Associated with Gastric Cancer Progression and Poor Survival of Patients

(2009) Z.-S. Zhao et al.   CLINICAL CANCER RESEARCH

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma

(2008) S R Park et al.   BRITISH JOURNAL OF CANCER

Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)

(2008) Masashi Fujii   International Journal of Clinical Oncology

The Copper Binding Domain of SPARC Mediates Cell Survivalin Vitrovia Interaction with Integrin β1 and Activation of Integrin-linked Kinase

(2008) Matt S. Weaver et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY

Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma

(2007) David E. Burstein et al.   Annals of Diagnostic Pathology